Literature DB >> 27074266

The role of germline alterations in the DNA damage response genes BRIP1 and BRCA2 in melanoma susceptibility.

Rainer Tuominen1, Pär G Engström2, Hildur Helgadottir1,3, Hanna Eriksson1,3, Per Unneberg2, Sanela Kjellqvist2, Muyi Yang1, Diana Lindén3, Daniel Edsgärd4, Johan Hansson1,3, Veronica Höiom1.   

Abstract

We applied a targeted sequencing approach to identify germline mutations conferring a moderately to highly increased risk of cutaneous and uveal melanoma. Ninety-two high-risk melanoma patients were screened for inherited variation in 120 melanoma candidate genes. Observed gene variants were filtered based on frequency in reference populations, cosegregation with melanoma in families and predicted functional effect. Several novel or rare genetic variants in genes involved in DNA damage response, cell-cycle regulation and transcriptional control were identified in melanoma patients. Among identified genetic alterations was an extremely rare variant (minor allele frequency of 0.00008) in the BRIP1 gene that was found to cosegregate with the melanoma phenotype. We also found a rare nonsense variant in the BRCA2 gene (rs11571833), previously associated with cancer susceptibility but not with melanoma, which showed weak association with melanoma susceptibility in the Swedish population. Our results add to the growing knowledge about genetic factors associated with melanoma susceptibility and also emphasize the role of DNA damage response as an important factor in melanoma etiology.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27074266     DOI: 10.1002/gcc.22363

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

1.  Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation.

Authors:  Anson Snow; Charite Ricker; Gino K In
Journal:  BMJ Case Rep       Date:  2019-06-20

2.  Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.

Authors:  Thomas P Potjer; Sander Bollen; Anneliese J E M Grimbergen; Remco van Doorn; Nelleke A Gruis; Christi J van Asperen; Frederik J Hes; Nienke van der Stoep
Journal:  Int J Cancer       Date:  2019-01-21       Impact factor: 7.396

3.  Melanoma predisposition-A limited role for germline BRCA1 and BRCA2 variants.

Authors:  David J Adams; David Timothy Bishop; Carla Daniela Robles-Espinoza
Journal:  Pigment Cell Melanoma Res       Date:  2019-10-28       Impact factor: 4.693

4.  Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.

Authors:  Dorra Ben Ayed-Guerfali; Wala Ben Kridis-Rejab; Nihel Ammous-Boukhris; Wajdi Ayadi; Slim Charfi; Afef Khanfir; Tahia Sellami-Boudawara; Mounir Frikha; Jamel Daoud; Raja Mokdad-Gargouri
Journal:  J Transl Med       Date:  2021-03-16       Impact factor: 5.531

5.  Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family.

Authors:  Raffaele Palmirotta; Domenica Lovero; Luigia Stefania Stucci; Erica Silvestris; Davide Quaresmini; Angela Cardascia; Franco Silvestris
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

6.  BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population.

Authors:  Tadeusz Dębniak; Rodney J Scott; Bohdan Górski; Bartłomiej Masojć; Andrzej Kram; Romuald Maleszka; Cezary Cybulski; Katarzyna Paszkowska-Szczur; Aniruddh Kashyap; Dawid Murawa; Karolina Malińska; Magdalena Kiedrowicz; Emilia Rogoża-Janiszewska; Helena Rudnicka; Jakub Deptuła; Paweł Domagała; Wojciech Kluźniak; Marcin R Lener; Jan Lubiński
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.